November 10, 2015 — Law360 reports that diabetes drug-makers are shielded from failure-to-warn claims involving pancreatic cancer because the FDA would have rejected warning labels, a federal judge has ruled. “Trelagliptin: First Global Approval”. By increasing the GLP-1 levels, ZYDPLA1 glucose-dependently increases insulin secretion and lowers glucagon secretion. India’s Gliptin market, estimated at Rs 2,000 crore yearly, is growing at around 60 per cent annually. This results in an overall improvement in the glucose homoeostasis, including reduction in HbA1c and blood sugar levels. Diabetes is fast gaining the status of a potential epidemic in India with over 67 million individuals currently diagnosed with the disease (source: IDF 2014), while there is a huge undiagnosed diabetes population estimated around 35.4 million. This causes increased basal insulin release so that plasma glucose can be kept within the normal range.
Therefore, launch of Dynaglipt has brought a hope for anti-diabetic therapy to patients in India. 45 per day treatment. lantus etc) may need to check BMs regularly. “There are many treatment options for diabetes — they have the benefit of lowering blood sugar levels, but they also carry risk,” said Dr. Robert Courgi, an endocrinologist at Northwell Health’s Southside Hospital in Bay Shore, N.Y. He said that standard guidelines typically list metformin as a first-line therapy against type 2 disease, but additional drugs may be needed. “Ultimately, the physician and the patient need to work together to find the best treatment possible,” Courgi said.